Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation.
about
Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro dataFluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4Reliability and extension of quantitative prediction of CYP3A4-mediated drug interactions based on clinical dataEvidence for substrate-dependent inhibition profiles for human liver aldehyde oxidase.Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin.Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction.Modulation of Hepatic Cytochrome P450 Enzymes by Curcumin and its Pharmacokinetic Consequences in Sprague-dawley RatsEffect of blueberry juice on clearance of buspirone and flurbiprofen in human volunteers.Contribution of baicalin on the plasma protein binding displacement and CYP3A activity inhibition to the pharmacokinetic changes of nifedipine in rats in vivo and in vitro.A useful tool for drug interaction evaluation: the University of Washington Metabolism and Transport Drug Interaction Database.The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance.Modeling and predicting drug pharmacokinetics in patients with renal impairment.In vitro-to-in vivo predictions of drug-drug interactions involving multiple reversible inhibitors.Advances in epilepsy treatment: lacosamide pharmacokinetic profile.Novel pre-clinical methodologies for pharmacokinetic drug-drug interaction studies: spotlight on "humanized" animal models.Potential drug interactions associated with glycyrrhizin and glycyrrhetinic acid.Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS).Effect of Low-Furanocoumarin Hybrid Grapefruit Juice Consumption on Midazolam Pharmacokinetics.Physiologically Based Pharmacokinetic (PBPK) Modeling of Pitavastatin and Atorvastatin to Predict Drug-Drug Interactions (DDIs).Preparation of labeled human drug metabolites and drug-drug interaction-probes with fungal peroxygenases.Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling.Evaluation of Time Dependent Inhibition Assays for Marketed Oncology Drugs: Comparison of Human Hepatocytes and Liver Microsomes in the Presence and Absence of Human Plasma.Preparation and Evaluation of Potent Pentafluorosulfanyl-Substituted Anti-Tuberculosis Compounds.Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment.A highly selective probe for human cytochrome P450 3A4: isoform selectivity, kinetic characterization and its applications.Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential.Prediction of cytochrome P450-mediated drug clearance in humans based on the measured activities of selected CYPs.Effects of Grapefruit and Pomegranate Juices on the Pharmacokinetic Properties of Dapoxetine and Midazolam in Healthy Subjects.Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach.Identification of cytochrome P450s involved in the metabolism of 6-benzyl-1-benzyloxymethyl-5-iodouracil (W-1) using human recombinant enzymes and rat liver microsomes in vitro."Drugs on oxygen": an update and perspective on the role of cytochrome P450 testing in pharmacology.Pomegranate juice does not affect the disposition of simvastatin in healthy subjects.Modulation of Cytochrome P450 Activity by 18β-Glycyrrhetic Acid and its Consequence on Buspirone Pharmacokinetics in Rats.
P2860
Q27009128-61A6E588-E232-40D8-B21D-94212C18485CQ28307990-7D8D588F-391D-43FA-91B1-39DCC2732CEDQ30856965-17F2CDE6-AF8C-4B5F-BE9D-5C8C29AE4115Q31814815-70E5CC52-E1C8-4923-B522-70962432436FQ33870649-7C511F6C-118E-4E88-A009-2DD681088F3EQ36578060-3E93DBAE-E9C7-41FC-BB8F-3CF44776FE73Q36675712-21D28665-EA65-4EE9-B778-738155886473Q36729945-81B83862-5BD0-43BF-B0A0-0326EEE653A9Q37534607-82A5A1F9-621D-4386-AE83-E0342B1A7263Q37812191-F75A16D0-0064-406F-BC97-A11CA24BBC62Q37955160-71267530-D49E-41B6-889B-6624531556C2Q37960638-7EAF3770-3640-4EEC-A16C-42D9CF81669CQ37989979-9FAFF9F6-D51C-4F93-83A7-6FABAB83C8F2Q38244248-4402FE69-53D8-4DB9-93D2-0FCE9A3B8C2FQ38255685-6EA85127-45E6-4B90-9278-10FD827CE571Q38397138-9A1A3709-BABC-412A-B0D8-A6C78C7C7B4AQ38855314-98BA29A8-0EA2-4256-81AB-5324F84D9E3FQ38922421-3E7C4BEB-1F07-4AB8-B80F-4BFFC32F502CQ39178447-366D1889-5531-4622-A866-96345A359DC9Q39305815-494D77DB-68D1-4986-B2FD-4A46AF23DE74Q39639310-D7504083-7F71-4CD9-997A-9D22E0CBB7A6Q40003126-34DB05C8-A99C-4AED-A3DD-7ECE4F748F0BQ40156484-84A5701B-4D64-40F7-A358-1DE6FBEF0FDAQ42146760-AC05C18C-5FD0-48A5-A3B2-858FDE08C866Q43696961-361F52D8-B5A3-439A-A740-3BE8B94E4A07Q43767845-1B8B8FE1-D1E8-4DF9-B3DC-9E5A7C11D619Q44677954-37D1885C-1437-4408-A1B8-1CBFF0766597Q46303402-8D3EC6C3-BDF3-459A-A054-9A88FEB272D3Q48500206-E2CE12D5-1681-42E9-940E-6A6A45E7B621Q51031739-B2541F52-AC85-43BF-B10C-D43777331D32Q51557998-4C673AFA-A4A3-47F1-9F47-3C57CC6909E8Q53304509-11DC5649-C1B0-40FB-BADB-3972694F8A9AQ53492647-2B7F157F-EA09-48AF-A778-6D1A85CE2FDE
P2860
Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Selection of alternative CYP3A ...... o data and in vivo simulation.
@ast
Selection of alternative CYP3A ...... o data and in vivo simulation.
@en
Selection of alternative CYP3A ...... o data and in vivo simulation.
@nl
type
label
Selection of alternative CYP3A ...... o data and in vivo simulation.
@ast
Selection of alternative CYP3A ...... o data and in vivo simulation.
@en
Selection of alternative CYP3A ...... o data and in vivo simulation.
@nl
prefLabel
Selection of alternative CYP3A ...... o data and in vivo simulation.
@ast
Selection of alternative CYP3A ...... o data and in vivo simulation.
@en
Selection of alternative CYP3A ...... o data and in vivo simulation.
@nl
P2093
P356
P1476
Selection of alternative CYP3A ...... o data and in vivo simulation.
@en
P2093
Dan A Rock
Jan L Wahlstrom
Larry C Wienkers
Robert S Foti
P304
P356
10.1124/DMD.110.032094
P577
2010-03-04T00:00:00Z